loader2
Partner With Us NRI

Company details

120.45
124.65
50.70
267.20
6M Return -11.17%
1Y Return 90.43%
Mkt Cap.(Cr) 345.57
Volume 5,172
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 5,172

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: -25.09 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 22,733.13 -38,406.68
LAST 3M 72,017.19 -50,293.88
LAST 6M 138,790.76 -188,500.14
LAST 12M 206,712.84 -177,545.72

Information

  • About Company
  • Company Info
  • Listing Info
8.41
47.79%
4.6497
0%
0%
Description
  • Initially manufacturing formulations, Lyka Labs brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. `83. It also added a range of ayurvedic and animal health care products over the years. In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan. Lyka Exports is the subsidiary of the company. The company offers a broad range of antibiotics used as life-savers and to treat minor infections. It has a fairly widespread product base with tropical steroids for skin disorders, anti-cancer products, cardio-vascular drugs and anti-inflammatory products. Lyka introduced, in India, cough lozenges containing dextromethorphan hydrobromide (DMR), favoured internationally as an effective and safe cough suppressant. Lyka has two formulations division and a bulk drugs division. It also set up additional manufacturing facilities for ointments. As part of its diversification, it has invested in Relic Finance, a company carrying on the business of finance and merchant banking. A GOI-recognised Export House, it received the Certificate of Merit for its excellent export performance in 1993-94. In the same year, it received an award from CHEMEXCIL for its outstanding performance. During 1997-98, the company`s administrative office & plant at tarapur has been awarded ISO 9002 certification for its quality management system by SGS Yarsley International Certification Services Limited, UK. The production carried out at Bombay has been shifted to Tarapur and Ankleshwar in the year 1999-2000, inorder to achieve economies of scale and better compliance. The company has assigned Trade Marks and transferred technical, marketing know-how and allied rights pertaining to some of its products.

Read More

Registered Address

4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

Tel : 91-02646-221422/220549
Email : companysecretary:lykalabs.com
Website : http://www.lykalabs.com

Registrar

Sharex Dynamic (India) Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500259
NSE Code : LYKALABS
Book Closure Date (Month) : Jul
BSE Group : B
ISIN : INE933A01014

ICICIdirect Lyka Labs Ltd FAQ

You can buy Lyka Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lyka Labs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 25, 2022 01:05 PM the closing price of Lyka Labs Ltd was ₹ 120.45.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 25, 2022 01:05 PM, the market cap of Lyka Labs Ltd stood at ₹ 345.57.
The latest PE ratio of Lyka Labs Ltd as of May 25, 2022 01:05 PM is 8.41
The latest PB ratio of Lyka Labs Ltd as of May 25, 2022 01:05 PM is 0.04
The 52-week high of Lyka Labs Ltd is ₹ 267.20 while the 52-week low is ₹ 50.70 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE